Biotech Stocks Facing FDA Decision In July 2021

1 / 14

In June, as of this writing, two novel drugs have secured the FDA nod – Brexafemme and Aduhelm.

Brexafemme, an antifungal drug developed by Scynexis Inc. (SCYX), was approved on June 1 to treat vulvovaginal candidiasis in adult females and pediatric females who have begun menstruating. A four-tablet course of treatment with Brexafemme is expected to cost between $350 and $450.

Aduhelm, the first new drug for Alzheimer's disease in nearly 20 years, was approved on June 7.The FDA approved Aduhelm despite its advisory panel not backing the drug. Aaron Kesselheim, one of the three members of the advisory panel, who resigned in protest of the FDA decision said that the approval of Aduhelm was the “worst drug approval decision” in recent history.